14,878 results match your criteria carcinoma rcc


Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden.

PLoS One 2021 22;16(6):e0253236. Epub 2021 Jun 22.

Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.

Global survival studies have shown favorable development in renal cell carcinoma (RCC) treatment but few studies have considered extended periods or covered populations for which medical care is essentially free of charge. We analyzed RCC survival in Finland and Sweden over a 50-year period (1967-2016) using data from the NORDCAN database provided by the local cancer registries. While the health care systems are largely similar in the two countries, the economic resources have been stronger in Sweden. Read More

View Article and Full-Text PDF

Renal cell carcinoma, part 1.

Authors:
Richard L Pullen

Nursing 2021 Jul;51(7):34-40

Richard L. Pullen is a professor of nursing at Texas Tech University Health Sciences Center School of Nursing in Lubbock, Tex., and is a member of the Nursing2021 editorial board.

Abstract: Renal cell carcinoma (RCC) encompasses a group of malignancies that originate in the epithelium of the renal cortex, most often in the upper pole of the kidney. This article, the first of a three-part series on RCC, addresses the incidence and epidemiology of RCC along with its genetic alterations, risk factors, histologic characteristics, and imaging characteristics. Read More

View Article and Full-Text PDF

A patient with very early onset FH-deficient renal cell carcinoma diagnosed at age seven.

Fam Cancer 2021 Jun 22. Epub 2021 Jun 22.

Department of Pediatrics, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan.

Hereditary leiomyomatosis and renal cell cancer (HLRCC) is caused by heterozygous germline variants in the fumarate hydratase (FH) gene and is associated with increased susceptibility to cutaneous leiomyomas, uterine leiomyomas, and renal cell carcinoma (RCC). HLRCC-associated RCC usually occurs in the middle age, with the median age being 40-44 years. This report describes a seven-year-old (84-month-old) male who developed a large right kidney tumor with multiple cystic lesions that contained enhanced solid components. Read More

View Article and Full-Text PDF

Co-existence of ESC-RCC, EVT, and LOT as synchronous and metachronous tumors in six patients with multifocal neoplasia, but without clinical features of tuberous sclerosis complex.

Hum Pathol 2021 Jun 18. Epub 2021 Jun 18.

Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA.

Renal cell tumors with oncocytic phenotypes represent a daily challenge with several novel, emerging, and provisional entities enriching the diagnostic repertoire. Eosinophilic solid and cystic renal cell carcinoma (ESC-RCC), low-grade oncocytic tumor (LOT), and eosinophilic vacuolated tumor (EVT) have been recognized as unique entities, although their distinctive nature remains controversial. Although most of these tumors are sporadic, rare reports of similar tumors in tuberous sclerosis complex (TSC) have been published. Read More

View Article and Full-Text PDF

Application of the ACMG/NSGC genetic referral guidelines for hereditary renal cell carcinoma at the University of Miami, from 2014 to 2017.

Am J Med Genet A 2021 Jun 21. Epub 2021 Jun 21.

Department of Human Genetics, University of Miami, Miller School of Medicine, Miami, Florida, USA.

Identifying hereditary syndromes among patients with renal cell carcinoma (RCC) is essential for surveillance of affected individuals and their at-risk family members and for treatment optimization. We conducted a chart review to determine the percentage of patients with RCC who were seen at the University of Miami Health System (UHealth), and met the American College of Medical Genetics (ACMG) and the National Society of Genetic Counselors (NSGC) genetic referral criteria at the University of Miami. Subsequently, we determined the percentage of those who went on to receive genetic evaluation. Read More

View Article and Full-Text PDF

Page Kidney From a Subcapsular Urinoma Following Contralateral Radical Nephrectomy.

Cureus 2021 Jun 14;13(6):e15639. Epub 2021 Jun 14.

Nephrology, Baylor Scott & White Medical Center - Temple, Temple, USA.

Page kidney is a rare cause of hypertension and kidney injury; it results from extrinsic compression of the kidney due to fluid accumulation in the subcapsular space. Hypertensive crisis may be the only presenting clinical sign in patients with Page kidney. Urinomas are a very rare cause of Page kidney with very few cases reported in the literature. Read More

View Article and Full-Text PDF

Synchronous Metastatic Clear Cell Renal Cell Carcinoma to the Gallbladder With Metachronous Contralateral Recurrence.

Cureus 2021 May 13;13(5):e15007. Epub 2021 May 13.

Department of Urology, University of South Florida, Tampa, USA.

Renal cell carcinoma (RCC) classically metastasizes to the lungs, bones, adrenals, lymph nodes, liver, and brain. RCC metastasis to the gallbladder is rare occurring in less than 1% of metastases. We present a case of a 60-year-old male who at initial diagnosis of his large left renal mass was incidentally found to have a gallbladder mass. Read More

View Article and Full-Text PDF

Diagnostic utility of one-stop fusion gene panel to detect TFE3/TFEB gene rearrangement and amplification in renal cell carcinomas.

Mod Pathol 2021 Jun 19. Epub 2021 Jun 19.

Department of Pathology, The University of Alabama at Birmingham, Birmingham, AL, USA.

MiT family translocation renal cell carcinoma (MiT-RCC) harbors translocations involving the TFE3 or TFEB genes. RCC with TFEB amplification is also identified and is associated with a more aggressive clinical course. Accurate diagnosis of MiT-RCC is crucial for patient management. Read More

View Article and Full-Text PDF

CT evaluation of patent artery after percutaneous cryoablation of renal cell carcinoma.

Diagn Interv Imaging 2021 Jun 15. Epub 2021 Jun 15.

Department of Radiology, Okayama University Medical School, 2-5-1 Shikata-cho kita-ku, 700-8558 Okayama, Japan.

Purpose: The purpose of this retrospective study was to determine the incidence of persistent patent artery after percutaneous cryoablation of renal cell carcinoma (RCC) and the relationship between patent arteries one month after cryoablation and early tumor progression.

Materials And Methods: One hundred and fifty-nine patients (112 men, 47 women; mean age, 63.6±14. Read More

View Article and Full-Text PDF

Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.

Lancet Oncol 2021 Jun 15. Epub 2021 Jun 15.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Background: Despite advances in the first-line treatment of metastatic renal cell carcinoma (RCC), there is an unmet need for options to address disease progression during or after treatment with immune checkpoint inhibitors (ICIs). Pembrolizumab and lenvatinib are active as monotherapies in RCC; thus, we aimed to evaluate the combination of lenvatinib plus pembrolizumab in these patients.

Methods: We report results of the metastatic RCC cohort from an open-label phase 1b/2 study of lenvatinib plus pembrolizumab in patients aged at least 18 years with selected solid tumours and an Eastern Cooperative Oncology Group performance status of 0-1. Read More

View Article and Full-Text PDF

A phase I study of APX005M and cabiralizumab with/without nivolumab in patients with melanoma, kidney cancer or non-small cell lung cancer resistant to anti-PD-(L)1.

Clin Cancer Res 2021 Jun 17. Epub 2021 Jun 17.

Smilow Cancer Center, Yale School of Medicine.

Purpose: PD-1/PD-L1 inhibitors are approved for multiple tumor types. However, resistance poses substantial clinical challenges.

Methods: We conducted a phase I trial of CD40 agonist APX005M (sotigalimab) and CSF1R inhibitor cabiralizumab with/without nivolumab using a 3+3 dose escalation design (NCT03502330). Read More

View Article and Full-Text PDF

Anti-neoplastic and demethylating activity of a newly synthetized flavanone-derived compound in Renal Cell Carcinoma cell lines.

Biomed Pharmacother 2021 Jun 15;141:111681. Epub 2021 Jun 15.

Cancer Biology and Epigenetics Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto 4200-072, Portugal; Department of Pathology and Molecular Immunology, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, Porto 4050-313, Portugal. Electronic address:

Renal Cell Carcinoma (RCC) is on the top 10 of the most incident cancers worldwide, being a third of patients diagnosed with advanced disease, for which no curative therapies are currently available. Thus, new effective therapeutic strategies are urgently needed. Herein, we tested the antineoplastic effect of newly synthesized 3-nitroflavanones (MLo1302) on RCC cell lines. Read More

View Article and Full-Text PDF

New frontiers against sorafenib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers.

Pharmacol Res 2021 Jun 15;170:105732. Epub 2021 Jun 15.

State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu 610041, PR China. Electronic address:

Renal cell carcinoma (RCC) is a highly vascularized tumor and prone to distant metastasis. Sorafenib is the first targeted multikinase inhibitor and first-line chemical drug approved for RCC therapy. In fact, only a small number of RCC patients benefit significantly from sorafenib treatment, while the growing prevalence of sorafenib resistance has become a major obstacle for drug therapy effectivity of sorafenib. Read More

View Article and Full-Text PDF

Added Value of Systemic Inflammation Markers in Predicting Clinical Stage T1 Renal Cell Carcinoma Pathologically Upstaged to T3a.

Front Oncol 2021 31;11:679536. Epub 2021 May 31.

Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Objectives: We aimed to determine preoperative risk factors associated with pathologic T3a (pT3a) upstaging of clinical T1 (cT1) renal cell carcinomas (RCCs) and develop a novel model capable of accurately identifying those patients at high risk of harboring occult pT3a characteristics.

Methods: A retrospective analysis of 1324 cT1 RCC patients who underwent partial nephrectomy (PN) or radical nephrectomy (RN) was performed. The study cohort was divided into training and testing datasets in a 70:30 ratio for further analysis. Read More

View Article and Full-Text PDF

Solitary metastasis of clear cell renal cell carcinoma in sternum diagnosed unexpectedly during cardiac surgery - A rare but potentially fatal trap.

Urol Case Rep 2021 Sep 28;38:101730. Epub 2021 May 28.

The Fingerland Department of Pathology, Charles University Faculty of Medicine in Hradec Kralove and University Hospital Hradec Kralove, Czech Republic.

We present a very rare case of fatal complication during the cardiac surgery caused by unrecognized solitary metastasis of clear cell renal cell carcinoma in the sternum. Read More

View Article and Full-Text PDF
September 2021

The Efficacy of Surgical Metastasectomy for Solitary Metastasis of Renal Cell Carcinoma.

Urol Int 2021 Jun 16:1-7. Epub 2021 Jun 16.

Division of Urology, Kobe University Graduate School of Medicine, Kobe, Japan.

Background: Patients with solitary metastasis of renal cell carcinoma (RCC) have shown to be ideal candidates for surgical metastasectomy (SM). However, whether SM will show more benefit than systemic therapy remains unclear.

Methods: We included 73 patients treated for solitary metastasis after nephrectomy at our institute from April 2008 to December 2018. Read More

View Article and Full-Text PDF

Hypoxic TAM-derived exosomal miR-155-5p promotes RCC progression through HuR-dependent IGF1R/AKT/PI3K pathway.

Cell Death Discov 2021 Jun 15;7(1):147. Epub 2021 Jun 15.

Department of Urology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.

Hypoxic tumor-associated macrophages (TAMs) are related to poor prognosis of patients with clear cell renal cell carcinoma (ccRCC). Exosomes are small lipid-bilayer vesicles that implicated in tumor progression and metastasis. However, whether hypoxic TAM-derived exosomes affect RCC progression within the hypoxic tumor microenvironment has not been elucidated. Read More

View Article and Full-Text PDF

Adrenalectomy During Radical Nephrectomy- Incidence and Oncologic Outcomes from the Canadian Kidney Cancer Information System (CKCis) -A Modern Era, Nationwide, Multicenter Cohort.

Urology 2021 Jun 12. Epub 2021 Jun 12.

Urology Division, Department of Surgery, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada. Electronic address:

Objective: To characterize proportion of patients receiving adrenalectomy, adrenal involvement prevalence and oncologic outcomes of routine adrenalectomy in contemporary practice. Ipsilateral adrenalectomy was once standard during radical nephrectomy. However, benefit of routine adrenalectomy has been questioned because adrenal involvement of renal cell carcinoma (RCC) is low. Read More

View Article and Full-Text PDF

An update on the pathology of collecting duct & papillary renal cell carcinoma with a discussion of SNP-Arrays as an emerging laboratory technique.

Authors:
Sounak Gupta

Urol Oncol 2021 Jun 11. Epub 2021 Jun 11.

Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN. Electronic address:

The diagnostic criteria and management of renal cell carcinoma (RCC) has evolved significantly in the last two decades. Increased molecular profiling of RCC has yielded further refinement of existing diagnostic categories. This is particularly true for papillary RCC, which has evolved into multiple molecularly distinct entities. Read More

View Article and Full-Text PDF

Analyzing and Validating the Prognostic Value of a TNF-Related Signature in Kidney Renal Clear Cell Carcinoma.

Front Mol Biosci 2021 28;8:689037. Epub 2021 May 28.

The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.

Kidney renal clear cell carcinoma (KIRC) has the highest incidence rate in renal cell carcinoma (RCC). Although bioinformatics is widely used in cancer, few reliable biomarkers of KIRC have been found. Therefore, continued efforts are required to elucidate the potential mechanism of the biogenesis and progression of KIRC. Read More

View Article and Full-Text PDF

A rare case of giant chromophobe renal cell carcinoma with sarcomatoid differentiation: Treatment and prognosis.

J Cancer Res Ther 2021 Apr-Jun;17(2):602-605

Department of Pathology, JIPMER, Puducherry, India.

Chromophobe renal cell carcinoma (RCC) with sarcomatoid differentiation is an infrequent entity. In the current era of advanced imaging techniques, RCCs are usually detected in early stages, and a localized giant tumor is rarely encountered. Recently, we encountered a patient with a localized giant RCC, which was 36 cm in the largest dimension and weighing 5. Read More

View Article and Full-Text PDF

A rare case of bilateral synchronous renal tumors with different histology successfully treated with bilateral partial nephrectomy.

J Cancer Res Ther 2021 Apr-Jun;17(2):593-595

Department of Biomedical Engineering, MIET, Bhubaneswar, Odisha, India.

Renal cell carcinoma (RCC) accounts for about 85% of all renal neoplasms, 60% of which are diagnosed incidentally. Most are unilateral, but bilateral tumors, synchronous or asynchronous, have been found in 2%-4% of reported sporadic cases. The occurrence of synchronous bilateral renal neoplasms with different histology in the same individual is very rare. Read More

View Article and Full-Text PDF

Recurrence of renal cell carcinoma after three decades in an octogenarian: Small molecules adding life to years.

J Cancer Res Ther 2021 Apr-Jun;17(2):584-586

Department of Medical Oncology and Hematology, Amrita Institute of Medical Sciences, Ponekkara, Kochi, Kerala, India.

Renal cell carcinoma (RCC) is the most common primary renal neoplasm. About a half of our patients relapse after primary treatment. We present here a case of RCC with solitary metastasis to the pleura which occurred 32 years after nephrectomy. Read More

View Article and Full-Text PDF

Differential effect of body mass index by gender on oncological outcomes in patients with renal cell carcinoma.

J Cancer Res Ther 2021 Apr-Jun;17(2):420-425

Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA.

Objectives: To investigate the relationship between gender, body mass index (BMI), and prognosis in renal cell carcinoma (RCC) patients.

Materials And Methods: We retrospectively reviewed 1353 patients with RCC who underwent a partial or radical nephrectomy between 1988 and 2015. The association among sex, BMI, stage, grade, overall survival (OS), and recurrence-free survival (RFS) was analyzed. Read More

View Article and Full-Text PDF

"Collecting duct carcinoma of the kidney: diagnosis and implications for management".

Urol Oncol 2021 Jun 8. Epub 2021 Jun 8.

Department of Pathology, City of Hope National Medical Center, Duarte, CA. Electronic address:

Collecting duct carcinoma of the kidney is a rare and aggressive subtype of renal cell carcinoma (RCC) arising from the distal convoluted tubules. At the time of diagnosis, patients are more frequently symptomatic, with advanced locoregional stage, and have metastatic disease. The 2016 WHO Classification of Tumours of the Urinary System defined diagnostic criteria for this entity. Read More

View Article and Full-Text PDF

Race/ethnicity and advanced stage of renal cell carcinoma in adults: results from surveillance, epidemiology, and end results program 2007-2015.

Eur J Cancer Prev 2021 Jun 10. Epub 2021 Jun 10.

Division of Medical and Population Health Sciences Research Department of Translational Medicine, Herbert Wertheim College of Medicine at Florida International University, Miami, Florida, USA.

Non-Hispanic Blacks were shown to have an earlier stage of renal cell carcinoma (RCC) at diagnosis compared to non-Hispanic Whites. It is less clear whether disparities in RCC staging occurs for other minority races/ethnicities. We aimed to assess the association between racial/ethnic minorities and stage at diagnosis of RCC, and test for potential effect modification by histological subtype. Read More

View Article and Full-Text PDF

Assessment of predictors of renal cell carcinoma progression after nephrectomy at short and intermediate term follow-up and implication on surveillance protocols.

Minerva Urol Nephrol 2021 Jun 11. Epub 2021 Jun 11.

Division of Urology, Department of Translational Medicine, Maggiore della Carità Hospital, University of Eastern Piedmont, Novara, Italy -

Background: Prediction of risk of RCC progression after surgery is important for follow-up planning. We identified predictors of progression-free survival (PFS) and cancer-specific survival (CSS) in a large single institutional cohort and investigated patterns and sites of progression according to stage and grade.

Methods: Node-negative non-metastatic clear-cell RCC (ccRCC) patients treated with radical or partial nephrectomy from 2000 to 2020 were included. Read More

View Article and Full-Text PDF

Hereditary Leiomyomatosis and Renal Cell Cancer: Recent Insights Into Mechanisms and Systemic Treatment.

Front Oncol 2021 25;11:686556. Epub 2021 May 25.

Department of Medical Laboratory, Shenzhen Longhua District Central Hospital, Shenzhen, China.

Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is a rare autosomal dominant hereditary cancer syndrome characterized by a predisposition to cutaneous leiomyomas, uterine leiomyomas, and renal cell carcinoma (RCC). It is known to be caused by germline mutations of the fumarate hydratase (FH) gene, which encodes an enzyme component of the citric acid cycle and catalyzes the conversion of fumarate to L-malate. Currently, there is no standardized treatment for HLRCC, which may be due in part to a lack of understanding of the underlying mechanisms. Read More

View Article and Full-Text PDF

Endobronchial Tumor With Ball Valve Mechanism: A Real Airway Emergency.

Cureus 2021 Jun 8;13(6):e15522. Epub 2021 Jun 8.

Interventional Pulmonology, Norton Thoracic Institute, Phoenix , USA.

Central airway obstruction due to the tumor can present as near-complete tracheal obstruction. The results can be life-threatening requiring emergent intervention. Rigid bronchoscopy has been preferred for the management of central airway obstruction. Read More

View Article and Full-Text PDF

CTCs detection from intraoperative salvaged blood in RCC-IVC thrombus patients by negative enrichment and iFISH identification: a preliminary study.

BMC Urol 2021 Jun 10;21(1):89. Epub 2021 Jun 10.

Department of Anesthesia, Peking University Third Hospital, Huayuan 49# Rd, Haidian Dist., Beijing, China.

Background: Intra-operative cell salvage (IOCS) and leukocyte-depleted filter (LDF) are widely used and effective in saving blood. However, the safety issue concerning reinfusion of IOCS-LDF processed blood to renal cell carcinoma (RCC) patients with inferior vena cava (IVC) thrombus were inconclusive for fear of increased risk of cancer metastases. This study intends to analyze the circulating tumor cell (CTC) eliminating effect of IOCS-LDF in 5 RCC-IVC thrombus patients. Read More

View Article and Full-Text PDF